Compare ATEN & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATEN | IDYA |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.6B |
| IPO Year | 2014 | 2019 |
| Metric | ATEN | IDYA |
|---|---|---|
| Price | $37.02 | $37.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 16 |
| Target Price | $26.33 | ★ $52.86 |
| AVG Volume (30 Days) | 1.2M | ★ 1.6M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.90% | N/A |
| EPS Growth | N/A | ★ 61.90 |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $235,429,000.00 | $218,710,000.00 |
| Revenue This Year | $13.02 | N/A |
| Revenue Next Year | $10.82 | $201.05 |
| P/E Ratio | $214.82 | ★ N/A |
| Revenue Growth | 2.36 | ★ 3024.43 |
| 52 Week Low | $16.52 | $21.33 |
| 52 Week High | $38.39 | $40.58 |
| Indicator | ATEN | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 69.62 | 63.66 |
| Support Level | $17.10 | $29.51 |
| Resistance Level | N/A | $38.17 |
| Average True Range (ATR) | 1.48 | 1.87 |
| MACD | 0.10 | 0.46 |
| Stochastic Oscillator | 77.76 | 73.73 |
A10 Networks Inc is a provider of secure application and network infrastructure solutions for enterprises and service providers across on-premises, hybrid cloud, and distributed environments. The company's offerings include application delivery and traffic management, distributed denial-of-service (DDoS) protection, application and API security, and centralized management. It serves customers across multiple industries, including telecommunications, technology, financial services, public sector, industrial, retail, gaming, and education. The majority of the company's revenue is derived from the sale of secure networking and cybersecurity solutions and related maintenance and support services.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.